belatacept belatacept belatacept, sold under the brand name nulojix, is a fusion protein composed of the fc fragment of a human igg1 immunoglobulin linked to the extracellular domain of ctla-4, which is a molecule crucial in the regulation of t cell costimulation, selectively blocking the process of t-cell activation. it is intended to provide extended graft and transplant survival while limiting the toxicity generated by standard immune suppressing regimens, such as calcineurin inhibitors. it differs from abatacept (orencia) by only two amino acids. belataceptclinical datatrade namesnulojixahfs/drugs.commonographmedlineplusa606016license data eu ema: by inn us dailymed: belatacept us fda: belatacept pregnancycategory au: c routes ofadministrationintravenousatc codel04aa28 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only identifierscas number706808-37-9 ydrugbankdb06681 ychemspidernoneuniie3b2gi648akeggd03222 ny (what is this?) (verify) belatacept was developed by bristol-myers-squibb and approved by the u.s. food and drug administration (fda) on june 15, 2011.